RxDoctor Payments Data

Venkatesh Janakiraman, MD

Neurology · Bakersfield, CANPI 1629331988

Payments from drug & device makers

$12,431in general payments, 2019–2025

Across 599 payments — averaging $20.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • UCB, Inc.$965
  • Novartis$965
  • EMD Serono, Inc.$785
  • Merz Pharmaceuticals, LLC$734
  • Livanova USA, Inc.$698
  • plus $7K from 49 others

What the payments were for

  • Food & beverage$12,16598%
  • Education$2662%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)79$1,091
UCB, Inc.39$965
Novartis59$965
EMD Serono, Inc.32$785
Merz Pharmaceuticals, LLC31$734
Livanova USA, Inc.24$698
Biogen33$685
AstraZeneca(2 entities)21$589
Neurelis, Inc.23$571
Eisai Inc.23$390
Amgen(2 entities)15$369
Acadia Pharmaceuticals Inc14$318
Supernus Pharmaceuticals, Inc.18$314
SK Life Science, Inc.15$314
Argenx US, Inc.10$267
Neurocrine Biosciences, Inc.11$258
Teva Pharmaceuticals USA, Inc.15$236
Adamas Pharmaceuticals, Inc.10$226
Pfizer12$218
Kyowa Kirin, Inc.9$202
Lilly USA, LLC12$186
Abbott5$183
Sunovion Pharmaceuticals Inc.11$173
Biohaven Pharmaceutical Holding Company Ltd.9$132
Akcea Therapeutics, Inc.4$120
Lundbeck LLC5$99
Greenwich Biosciences, Inc.2$96
Ipsen Biopharmaceuticals, Inc5$89
Biohaven Pharmaceuticals, Inc.5$88
Merz North America, Inc.3$73
Catalyst Pharmaceuticals, Inc.3$68
Avanir Pharmaceuticals, Inc.4$68
Jazz Pharmaceuticals Inc.2$66
Bristol Myers Squibb3$65
Amylyx Pharmaceuticals, Inc.2$64
Ceribell, Inc.2$60
MDD US Operations, LLC1$57
Mallinckrodt Enterprises LLC3$54
Sumitomo Pharma America, Inc.2$53
ANI Pharmaceuticals, Inc.3$48
Johnson & Johnson(2 entities)2$44
Tanabe Pharma America, Inc.2$43
Alnylam Pharmaceuticals Inc.2$41
GRT US Holding, Inc.1$32
Otsuka America Pharmaceutical, Inc.2$26
Aquestive Therapeutics, Inc.2$26
Grifols USA, LLC1$25
Mallinckrodt Hospital Products Inc.1$24
Banner Life Sciences, LLC1$24
Takeda Pharmaceuticals U.S.A., Inc.1$22
Boston Scientific1$21
Genentech USA, Inc.1$20
Saol Therapeutics Inc.1$17
Travere Therapeutics, Inc.1$14
Zogenix Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,431 in reported general payments places this provider in the 75th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$267,529
Medicare patients
284
Services billed
9,380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Radicava OrsEdaravone12$153,633
NamzaricMemantine Hcl/Donepezil Hcl29$16,615
FycompaPerampanel12$14,254
Nurtec OdtRimegepant Sulfate15$13,227
Pramipexole ErPramipexole Di-Hcl11$3,845
Memantine Hcl204$2,893
Lacosamide46$2,258
Levetiracetam ErLevetiracetam22$2,067
Gabapentin204$1,749
Carbidopa-LevodopaCarbidopa/Levodopa107$1,389
AmantadineAmantadine Hcl24$1,154
Ropinirole ErRopinirole Hcl23$1,138
Ropinirole Hcl113$1,108
Pregabalin65$1,054
Propranolol Hcl77$935

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieNamzaric$1,091$16,61529 claims
Eisai Inc.Fycompa$390$14,25412 claims
PfizerNurtec Odt$218$13,22715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,996 neurology providers in California.

Other neurology in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →